Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma

Craig Moskowitz • 9 Apr 2015
ASH 2014
Hodgkin Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Pembrolizumab

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the preliminary results of a phase Ib study evaluating the PD-1 inhibitor, pembrolizumab, in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.

More from Craig Moskowitz

Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma
7:27
Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma
Craig Moskowitz • 5 Dec 2014
ASH 2014: Ask the experts Q&A session 1
23:35
ASH 2014: Ask the experts Q&A session 1
Catherine Bollard et al. • 6 Dec 2014

Related Videos

Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
1:16
Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
1:10
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
1:42
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
Cathy Burton • 6 Jul 2026
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
2:36
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
Cathy Burton • 14 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals